title: Weekly administration of alendronate: rationale and plan for clinical assessment.
abstract: OBJECTIVE
  This paper describes the rationale and supporting data for once-weekly dosing of alendronate.
  
  
  BACKGROUND
  Alendronate sodium, a bisphosphonate that potently inhibits bone resorption, has been shown to increase bone mass and substantially reduce the incidence of osteoporotic fractures, including fractures of the hip. The standard regimen of daily administration has generally been well tolerated. However, weekly administration may provide greater convenience to patients without compromising efficacy or tolerability. The pharmacokinetics of alendronate and bone remodeling theory predict similar efficacy for weekly and daily administration if the cumulative dose is the same. Bone resorption in individual remodeling units normally proceeds for approximately 2 weeks; alendronate inhibits the rate and extent of resorption. Because the half-life of residence on bone surfaces is several weeks, weekly administration of alendronate should inhibit bone resorption to an overall extent similar to that of daily dosing, thereby producing similar effects on bone mass and strength. Animal studies demonstrate that both weekly and daily parenteral administration of alendronate effectively increase bone mass and strength, but confirmation of efficacy is needed for weekly oral dosing in humans. Although daily bisphosphonates (alendronate and risedronate) elicited esophageal irritation in a canine model of gastroesophageal reflux, weekly dosing with alendronate at a higher unit dose did not. Thus, the lower frequency of weekly dosing with a higher unit dose may actually reduce the risk of upper gastrointestinal irritation compared with daily administration of a lower dose.
  
  
  CONCLUSIONS
  Current safety and efficacy data justify further investigation of once-weekly dosing of alendronate. Two positive-control, double-blind, randomized trials of osteoporosis treatment and prevention are currently being performed to assess the comparability of weekly, biweekly, and daily dosing of alendronate with regard to effects on bone density, safety, and tolerability.
authors.affiliation: Michigan Bone and Mineral Clinic, Detroit 48236-2161, USA.
authors.forename: H G
authors.initials: HG
authors.lastname: Bone
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.forename: R
authors.initials: R
authors.lastname: Rizzoli
authors.forename: M
authors.initials: M
authors.lastname: Favus
authors.forename: P D
authors.initials: PD
authors.lastname: Ross
authors.forename: A
authors.initials: A
authors.lastname: Santora
authors.forename: S
authors.initials: S
authors.lastname: Prahalada
authors.forename: A
authors.initials: A
authors.lastname: Daifotis
authors.forename: J
authors.initials: J
authors.lastname: Orloff
authors.forename: J
authors.initials: J
authors.lastname: Yates
mesh_terms: D019386:Alendronate / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy*; D004285:Dogs; D006801:Humans
chemical_list: D019386:Alendronate